Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
August 18, 2022 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year ...
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
July 28, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July ...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
June 09, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022...
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
May 18, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent...
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 16, 2022 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year ...
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
May 12, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
May 10, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
May 09, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 ...
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
April 28, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
April 27, 2022 13:43 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...